

<b>Audit Review Table</b>				
Blue Cross Blue Shield of New Mexico (Org ID: 1825, SubID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2019; Date & Timestamp - 6/10/2020 11:15:47 AM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
<b>Effectiveness of Care: Prevention and Screening</b>				
<b>Adult BMI Assessment (aba)</b>		83.45%	R	Reportable
<b>Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)</b>				
BMI Percentile		69.10%	R	Reportable
Counseling for Nutrition		55.96%	R	Reportable
Counseling for Physical Activity		45.50%	R	Reportable
<b>Childhood Immunization Status (cis)</b>				
DTaP		76.89%	R	Reportable
IPV		89.29%	R	Reportable
MMR		89.78%	R	Reportable
HIB		87.83%	R	Reportable
Hepatitis B		88.32%	R	Reportable
VZV		88.81%	R	Reportable
Pneumococcal Conjugate		76.64%	R	Reportable
Hepatitis A		90.51%	R	Reportable
Rotavirus		73.72%	R	Reportable
Influenza		52.80%	R	Reportable
Combination #2		73.24%	R	Reportable
Combination #3		70.80%	R	Reportable
Combination #4		70.56%	R	Reportable
Combination #5		63.26%	R	Reportable
Combination #6		43.80%	R	Reportable
Combination #7		63.02%	R	Reportable
Combination #8		43.80%	R	Reportable
Combination #9		40.63%	R	Reportable
Combination #10		40.63%	R	Reportable
<b>Immunizations for Adolescents (ima)</b>				
Meningococcal		77.86%	R	Reportable
Tdap		85.89%	R	Reportable
HPV		34.31%	R	Reportable
Combination #1		76.40%	R	Reportable
Combination #2		33.58%	R	Reportable
<b>Lead Screening in Children (lsc)</b>		43.25%	R	Reportable
<b>Breast Cancer Screening (bcs)</b>		43.19%	R	Reportable
<b>Cervical Cancer Screening (ccs)</b>		45.50%	R	Reportable
<b>Chlamydia Screening in Women (chl)</b>				
16-20 Years		46.95%	R	Reportable
21-24 Years		56.87%	R	Reportable
Total		51.61%	R	Reportable
<b>Effectiveness of Care: Respiratory Conditions</b>				
<b>Appropriate Testing for Pharyngitis (cwp)</b>	Y			
3-17 Years		76.48%	R	Reportable
18-64 Years		67.41%	R	Reportable
65+ Years		100.00%	NA	Small Denominator
Total		72.95%	R	Reportable
<b>Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)</b>		24.17%	R	Reportable
<b>Pharmacotherapy Management of COPD Exacerbation (pce)</b>	Y			
Systemic Corticosteroid		38.55%	R	Reportable
Bronchodilator		46.38%	R	Reportable
<b>Medication Management for People With Asthma (mma)</b>	Y			
5-11 Years: Medication Compliance 50%		58.28%	R	Reportable
5-11 Years: Medication Compliance 75%		31.36%	R	Reportable
12-18 Years: Medication Compliance 50%		56.39%	R	Reportable
12-18 Years: Medication Compliance 75%		29.07%	R	Reportable
19-50 Years: Medication Compliance 50%		69.08%	R	Reportable
19-50 Years: Medication Compliance 75%		41.89%	R	Reportable
51-64 Years: Medication Compliance 50%		74.78%	R	Reportable
51-64 Years: Medication Compliance 75%		55.22%	R	Reportable
Total: Medication Compliance 50%		64.91%	R	Reportable
Total: Medication Compliance 75%		39.17%	R	Reportable
<b>Asthma Medication Ratio (amr)</b>	Y			
5-11 Years		76.57%	R	Reportable

12-18 Years		63.37%	R	Reportable
19-50 Years		50.23%	R	Reportable
51-64 Years		57.69%	R	Reportable
Total		59.79%	R	Reportable
<b>Effectiveness of Care: Cardiovascular Conditions</b>				
<b>Controlling High Blood Pressure (cbp)</b>		54.50%	R	Reportable
<b>Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)</b>	Y	64.71%	R	Reportable
<b>Statin Therapy for Patients With Cardiovascular Disease (spc)</b>	Y			
Received Statin Therapy: 21-75 Years (Male)		66.32%	R	Reportable
Statin Adherence 80%: 21-75 Years (Male)		54.69%	R	Reportable
Received Statin Therapy: 40-75 Years (Female)		47.60%	R	Reportable
Statin Adherence 80%: 40-75 Years (Female)		55.96%	R	Reportable
Received Statin Therapy: Total		59.35%	R	Reportable
Statin Adherence 80%: Total		55.07%	R	Reportable
<b>Effectiveness of Care: Diabetes</b>				
<b>Comprehensive Diabetes Care (cdc)</b>				
Hemoglobin A1c (HbA1c) Testing		85.89%	R	Reportable
HbA1c Poor Control (>9.0%)		43.07%	R	Reportable
HbA1c Control (<8.0%)		46.47%	R	Reportable
HbA1c Control (<7.0%)			NR	Not Reported
Eye Exam (Retinal) Performed		48.66%	R	Reportable
Medical Attention for Nephropathy		87.35%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)		60.34%	R	Reportable
<b>Statin Therapy for Patients With Diabetes (spd)</b>	Y			
Received Statin Therapy		47.05%	R	Reportable
Statin Adherence 80%		55.28%	R	Reportable
<b>Effectiveness of Care: Behavioral Health</b>				
<b>Antidepressant Medication Management (amm)</b>	Y			
Effective Acute Phase Treatment		53.10%	R	Reportable
Effective Continuation Phase Treatment		37.35%	R	Reportable
<b>Follow-Up Care for Children Prescribed ADHD Medication (add)</b>	Y			
Initiation Phase		46.99%	R	Reportable
Continuation and Maintenance (C&M) Phase		50.93%	R	Reportable
<b>Follow-Up After Hospitalization for Mental Illness (fuh)</b>	Y			
6-17 years - 30-Day Follow-Up		55.45%	R	Reportable
6-17 years - 7-Day Follow-Up		36.09%	R	Reportable
18-64 years - 30-Day Follow-Up		38.51%	R	Reportable
18-64 years - 7-Day Follow-Up		23.29%	R	Reportable
65+ years - 30-Day Follow-Up		30.30%	R	Reportable
65+ years - 7-Day Follow-Up		15.15%	R	Reportable
Total - 30-Day Follow-Up		41.62%	R	Reportable
Total - 7-Day Follow-Up		25.61%	R	Reportable
<b>Follow-Up After Emergency Department Visit for Mental Illness (fum)</b>	Y			
6-17 years - 30-Day Follow-Up		78.72%	R	Reportable
6-17 years - 7-Day Follow-Up		59.49%	R	Reportable
18-64 years - 30-Day Follow-Up		50.49%	R	Reportable
18-64 years - 7-Day Follow-Up		36.33%	R	Reportable
65+ years - 30-Day Follow-Up		31.58%	NA	Small Denominator
65+ years - 7-Day Follow-Up		26.32%	NA	Small Denominator
Total - 30-Day Follow-Up		56.27%	R	Reportable
Total - 7-Day Follow-Up		41.13%	R	Reportable
<b>Follow-Up After High-Intensity Care for Substance Use Disorder (fui)</b>	Y			
13-17 years - 30-Day Follow-Up		0.00%	NA	Small Denominator
13-17 years - 7-Day Follow-Up		0.00%	NA	Small Denominator
18-64 years - 30-Day Follow-Up		41.11%	R	Reportable
18-64 years - 7-Day Follow-Up		18.08%	R	Reportable
65+ years - 30-Day Follow-Up		14.29%	NA	Small Denominator
65+ years - 7-Day Follow-Up		14.29%	NA	Small Denominator
Total - 30-Day Follow-Up		40.33%	R	Reportable
Total - 7-Day Follow-Up		17.82%	R	Reportable
<b>Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (fua)</b>	Y			
30-Day Follow-Up: 13-17 Years		9.52%	R	Reportable
7-Day Follow-Up: 13-17 Years		7.62%	R	Reportable
30-Day Follow-Up: 18+ Years		20.37%	R	Reportable
7-Day Follow-Up: 18+ Years		12.87%	R	Reportable

30-Day Follow-Up: Total		20.05%	R	Reportable
7-Day Follow-Up: Total		12.72%	R	Reportable
<b>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)</b>	Y	79.02%	R	Reportable
<b>Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)</b>		47.84%	R	Reportable
<b>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)</b>		57.14%	NA	Small Denominator
<b>Pharmacotherapy for Opioid Use Disorder (pod)</b>	Y			
16-64 years		22.45%	R	Reportable
65+ years		30.00%	NA	Small Denominator
Total		22.48%	R	Reportable
<b>Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)</b>	Y	51.88%	R	Reportable
<b>Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)</b>	Y			
Blood glucose testing - 1-11 Years		41.72%	R	Reportable
Cholesterol Testing - 1-11 Years		27.15%	R	Reportable
Blood glucose and Cholesterol Testing - 1-11 Years		25.50%	R	Reportable
Blood glucose testing - 12-17 Years		63.43%	R	Reportable
Cholesterol Testing - 12-17 Years		35.76%	R	Reportable
Blood glucose and Cholesterol Testing - 12-17 Years		34.55%	R	Reportable
Blood glucose testing - Total		55.21%	R	Reportable
Cholesterol Testing - Total		32.50%	R	Reportable
Blood glucose and Cholesterol Testing - Total		31.12%	R	Reportable
<b>Effectiveness of Care: Overuse/Appropriateness</b>				
<b>Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)</b>		0.89%	R	Reportable
<b>Appropriate Treatment for Upper Respiratory Infection (uri)</b>	Y			
3months-17 Years		87.52%	R	Reportable
18-64 Years		68.74%	R	Reportable
65+ Years		98.82%	R	Reportable
Total		82.51%	R	Reportable
<b>Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (aab)</b>	Y			
3 months-17 Years		61.49%	R	Reportable
18-64 Years		35.63%	R	Reportable
65+ Years		97.03%	R	Reportable
Total		50.04%	R	Reportable
<b>Use of Imaging Studies for Low Back Pain (lbp)</b>		72.84%	R	Reportable
<b>Use of Opioids at High Dosage (hdo)</b>	Y	5.13%	R	Reportable
<b>Use of Opioids From Multiple Providers (uop)</b>	Y			
Multiple Prescribers		18.31%	R	Reportable
Multiple Pharmacies		4.88%	R	Reportable
Multiple Prescribers and Multiple Pharmacies		2.32%	R	Reportable
<b>Risk of Continued Opioid Use (cou)</b>	Y			
18-64 years - >=15 Days covered		5.24%	R	Reportable
18-64 years - >=31 Days covered		3.15%	R	Reportable
65+ years - >=15 Days covered		23.08%	NA	Small Denominator
65+ years - >=31 Days covered		15.38%	NA	Small Denominator
Total - >=15 Days covered		5.26%	R	Reportable
Total - >=31 Days covered		3.16%	R	Reportable
<b>Access/Availability of Care</b>				
<b>Adults' Access to Preventive/Ambulatory Health Services (aap)</b>				
20-44 Years		73.80%	R	Reportable
45-64 Years		81.49%	R	Reportable
65+ Years		88.58%	R	Reportable
Total		77.22%	R	Reportable
<b>Children and Adolescents' Access to Primary Care Practitioners (cap)</b>				
12-24 Months		95.60%	R	Reportable
25 Months - 6 Years		88.53%	R	Reportable
7-11 Years		89.57%	R	Reportable
12-19 Years		87.96%	R	Reportable
<b>Annual Dental Visit (adv)</b>	Y			
2-3 Years		60.77%	R	Reportable
4-6 Years		76.08%	R	Reportable
7-10 Years		78.37%	R	Reportable
11-14 Years		73.54%	R	Reportable

15-18 Years		64.09%	R	Reportable
19-20 Years		44.58%	R	Reportable
Total		70.11%	R	Reportable
<b>Initiation and Engagement of AOD Abuse or Dependence Treatment (iet)</b>	Y			
Alcohol abuse or dependence: Initiation of AOD Treatment: 13-17 Years		35.79%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: 13-17 Years		4.21%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: 13-17 Years		61.11%	NA	Small Denominator
Opioid abuse or dependence: Engagement of AOD Treatment: 13-17 Years		16.67%	NA	Small Denominator
Other drug abuse or dependence: Initiation of AOD Treatment: 13-17 Years		43.91%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: 13-17 Years		12.55%	R	Reportable
Total: Initiation of AOD Treatment: 13-17 Years		40.88%	R	Reportable
Total: Engagement of AOD Treatment: 13-17 Years		11.18%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment: 18+ Years		38.81%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: 18+ Years		13.03%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: 18+ Years		55.77%	R	Reportable
Opioid abuse or dependence: Engagement of AOD Treatment: 18+ Years		25.78%	R	Reportable
Other drug abuse or dependence: Initiation of AOD Treatment: 18+ Years		38.82%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: 18+ Years		10.43%	R	Reportable
Total: Initiation of AOD Treatment: 18+ Years		41.06%	R	Reportable
Total: Engagement of AOD Treatment: 18+ Years		14.64%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment: Total		38.75%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: Total		12.83%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: Total		55.83%	R	Reportable
Opioid abuse or dependence: Engagement of AOD Treatment: Total		25.69%	R	Reportable
Other drug abuse or dependence: Initiation of AOD Treatment: Total		39.16%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: Total		10.57%	R	Reportable
Total: Initiation of AOD Treatment: Total		41.05%	R	Reportable
Total: Engagement of AOD Treatment: Total		14.51%	R	Reportable
<b>Prenatal and Postpartum Care (ppc)</b>				
Timeliness of Prenatal Care		84.43%	R	Reportable
Postpartum Care		64.48%	R	Reportable
<b>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)</b>	Y			
1-11 Years		61.86%	R	Reportable
12-17 Years		67.19%	R	Reportable
Total		64.89%	R	Reportable
<b>Utilization</b>				
<b>Well-Child Visits in the First 15 Months of Life (w15)</b>				
0 Visits		2.92%	R	Reportable
1 Visit		2.43%	R	Reportable
2 Visits		3.16%	R	Reportable
3 Visits		6.33%	R	Reportable
4 Visits		6.08%	R	Reportable
5 Visits		13.14%	R	Reportable
6+ Visits		65.94%	R	Reportable
<b>Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)</b>		63.75%	R	Reportable
<b>Adolescent Well-Care Visits (awc)</b>		38.42%	R	Reportable
<b>Frequency of Selected Procedures (fsp)</b>			R	Reportable
<b>Ambulatory Care: Total (amba)</b>			R	Reportable
<b>Ambulatory Care: Dual Eligibles (ambb)</b>			NR	Not Reported
<b>Ambulatory Care: Disabled (ambc)</b>			NR	Not Reported
<b>Ambulatory Care: Other (ambd)</b>			NR	Not Reported

Inpatient Utilization--General Hospital/Acute Care: Total (ipua)			R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)			NR	Not Reported
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)			NR	Not Reported
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)			NR	Not Reported
Identification of Alcohol and Other Drug Services: Total (iada)	Y		R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Y		NR	Not Reported
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Y		NR	Not Reported
Identification of Alcohol and Other Drug Services: Other (iadd)	Y		NR	Not Reported
Mental Health Utilization: Total (mpta)	Y		R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	Y		NR	Not Reported
Mental Health Utilization: Disabled (mptc)	Y		NR	Not Reported
Mental Health Utilization: Other (mptd)	Y		NR	Not Reported
Antibiotic Utilization: Total (abxa)	Y		R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Y		NR	Not Reported
Antibiotic Utilization: Disabled (abxc)	Y		NR	Not Reported
Antibiotic Utilization: Other (abxd)	Y		NR	Not Reported
<b>Risk Adjusted Utilization</b>				
Plan All-Cause Readmissions (pcr)			R	Reportable
<b>Health Plan Descriptive Information</b>				
Enrollment by Product Line: Total (enpa)			R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)			NR	Not Reported
Enrollment by Product Line: Disabled (enpc)			NR	Not Reported
Enrollment by Product Line: Other (enpd)			NR	Not Reported
Enrollment by State (ebs)			R	Reportable
Language Diversity of Membership (ldm)			NR	Not Reported
Race/Ethnicity Diversity of Membership (rdm)			NR	Not Reported
Total Membership (t1m)			R	Reportable
<b>Measures Collected using Electronic Clinical Data Systems</b>				
Follow-Up Care for Children Prescribed ADHD Medication (add-e)	Y			
<i>Initiation Phase</i>			NR	Not Reported
<i>Continuation and Maintenance Phase</i>			NR	Not Reported
Breast Cancer Screening (bcs-e)			NR	Not Reported
Depression Screening and Follow-Up for Adolescents and Adults (dsf)				
<i>Depression Screening: Total Total</i>			NR	Not Reported
<i>Follow-up on Positive Screen: Total Total</i>			NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)				
<i>Utilization of PHQ-9 - Time period 1: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Time period 2: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Time period 3: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Total: Total Total</i>			NR	Not Reported
Depression Remission or Response for Adolescents and Adults (drr)				
<i>Follow-up PHQ-9: Total Total</i>			NR	Not Reported
<i>Depression Remission: Total Total</i>			NR	Not Reported
<i>Depression Response: Total Total</i>			NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (asf)				
<i>Alcohol Use Screening: Total Total</i>			NR	Not Reported
<i>Counseling or Other Follow-up Positive Screen: Total Total</i>			NR	Not Reported
Adult Immunization Status (ais)				
<i>Influenza: Total</i>			NR	Not Reported
<i>Td or Tdap: Total</i>			NR	Not Reported
<i>Zoster: Total</i>			NR	Not Reported
<i>Composite: Total</i>			NR	Not Reported
Postpartum Depression Screening and Follow-Up (pds)				
<i>Depression Screening</i>			NR	Not Reported
<i>Follow-Up on Positive Screen</i>			NR	Not Reported
Prenatal Depression Screening and Follow-Up (pnd)				
<i>Depression Screening</i>			NR	Not Reported
<i>Follow-Up on Positive Screen</i>			NR	Not Reported
Prenatal Immunization Status (prs)				
<i>Influenza: Total</i>			NR	Not Reported

<i>Td or Tdap: Total</i>			NR	Not Reported
<i>Combination: Total</i>			NR	Not Reported